The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The effect of quality improvement interventions on inpatient cancer malnutrition documentation and coding in an academic medical center.
 
Aynur Aktas
No Relationships to Disclose
 
Lenna Finch
Honoraria - Baxter
Consulting or Advisory Role - Fresenius Kabi
Travel, Accommodations, Expenses - Baxter
 
Danielle Boselli
Employment - TERUMO (I)
Leadership - TERUMO (I)
Stock and Other Ownership Interests - TERUMO (I)
Travel, Accommodations, Expenses - TERUMO (I)
 
Declan Walsh
Leadership - Nualtra
Stock and Other Ownership Interests - Nualtra
Honoraria - Helsinn Therapeutics
Consulting or Advisory Role - Helsinn Therapeutics
Research Funding - Nualtra
 
Kunal C. Kadakia
No Relationships to Disclose
 
Lauren Dennis Giamberardino
No Relationships to Disclose
 
Beth York
No Relationships to Disclose
 
Sally Trufan
No Relationships to Disclose
 
Rupali Bose
Honoraria - Abbvie (I); Adaptive Biotechnologies (I); ADC Therapeutics (I); AstraZeneca (I); Bristol-Myers Squibb (I); Epizyme (I); Genmab (I); Gilead Sciences (I); Janssen Oncology (I); Karyopharm Therapeutics (I); Seagen (I); TG Therapeutics (I)
Consulting or Advisory Role - Abbvie (I); Adaptive Biotechnologies (I); ADC Therapeutics (I); AstraZeneca (I); Bristol-Myers Squibb (I); Epizyme (I); Genmab (I); Gilead Sciences (I); Janssen Oncology (I); Karyopharm Therapeutics (I); Seagen (I); TG Therapeutics (I)
Speakers' Bureau - Abbvie (I); AstraZeneca (I); Bristol-Myers Squibb (I); Epizyme (I); Gilead Sciences (I); Janssen Oncology (I)
Research Funding - Bristol-Myers Squibb (I); Genentech (I); Gilead Sciences (I); TG Therapeutics (I)